Skip to content
No results
renal lifecycle logo
  • Home
  • Organisation
    • Our Team
    • Funding
  • Participants
    • General information
    • Participation
    • Participating centers
    • Additional information
    • Newsletters
    • Patients talking
    • Frequently Asked Questions
  • Professionals
    • Trial background
    • Trial design
    • Participating centers
    • Additional information
    • Newsletters
    • FAQ
  • News
  • Feedback
  • Contact
  • English
  • Deutsch
  • Nederlands
renal lifecycle logorenal lifecycle logo
  • Home
  • Organisation
    • Our Team
    • Funding
  • Participants
    • General information
    • Participation
    • Participating centers
    • Additional information
    • Newsletters
    • Patients talking
    • Frequently Asked Questions
  • Professionals
    • Trial background
    • Trial design
    • Participating centers
    • Additional information
    • Newsletters
    • FAQ
  • News
  • Feedback
  • Contact

           

renal lifecycle logorenal lifecycle logo

"SGLT2 inhibitors should also be made available to those with highest risk of problem"

Newsletters

To share progress with participating centers, a newsletter will be made. This newsletter will be shared by email, but can also be found below.

Newsletter summer 2022
Newsletter summer 2023
Newsletter November 2023
Newsletter December 2023
Newsletter January 2024
Newsletter February 2024
Newsletter March 2024
Newsletter April 2024
Newsletter May 2024
Newsletter June 2024
Newsletter July 2024
Newsletter September 2024
Newsletter October 2024
Newsletter November 2024
Newsletter January 2025
Newsletter February 2025
Newsletter March 2025
Newsletter April 2025
Newsletter May 2025
Newsletter June 2025
Newsletter August 2025
Newsletter Sept/Oct 2025
Newsletter January 2026

Partners

http://UMCG
http://Nieren.nl
http://Nierstichting
http://Nierpatiënten%20vereniging%20Nederland
http://AstraZeneca
http://The%20George%20Institute%20for%20Global%20Health

Copyright © 2026 - YMRAB